TVWM
CRL icon

Tower View Wealth Management’s Charles River Laboratories CRL Stock Holding History

Tower View Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20
Closed -$6K – 178
2021
Q1 		$6K Buy
+20
New +$5.56K ﹤0.01% 155

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Tower View Wealth Management's CRL Position: Q2 2021 in Review

Tower View Wealth Management sold out of Charles River Laboratories (CRL) in Q2 2021, closing a stake of 20 shares — an estimated $6K sold.

Tower View Wealth Management first reported a position in CRL in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 638 funds tracked by Wall St. Rank hold CRL as of Q2 2021.

  • Tower View Wealth Management reported no remaining Charles River Laboratories position as of Q2 2021 after selling out during the quarter.
  • Tower View Wealth Management sold 20 Charles River Laboratories shares in Q2 2021, an estimated $6K.
  • Tower View Wealth Management first reported a position in Charles River Laboratories in Q1 2021 and held it in 1 quarter.
  • Tower View Wealth Management's Charles River Laboratories position peaked at $6K in Q1 2021.
  • 638 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2021.

Based on Tower View Wealth Management's 13F filing for Q2 2021, filed 28 Jul 2021.